vs

Side-by-side financial comparison of Lineage Cell Therapeutics, Inc. (LCTX) and Valaris Ltd (VAL). Click either name above to swap in a different company.

Lineage Cell Therapeutics, Inc. is the larger business by last-quarter revenue ($6.6M vs $5.2M, roughly 1.3× Valaris Ltd). Valaris Ltd runs the higher net margin — 13798.1% vs 12.9%, a 13785.2% gap on every dollar of revenue. On growth, Valaris Ltd posted the faster year-over-year revenue change (405.9% vs 130.4%). Lineage Cell Therapeutics, Inc. produced more free cash flow last quarter ($-5.3M vs $-34.1M). Over the past eight quarters, Lineage Cell Therapeutics, Inc.'s revenue compounded faster (113.9% CAGR vs 29.5%).

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to eithe...

Valaris Limited is an offshore drilling contractor headquartered in Houston, Texas, and incorporated in Bermuda. It is the largest offshore drilling and well drilling company in the world. As of February 2025, it owned 52 rigs, including 36 offshore jackup rigs, 11 drillships, and 5 semi-submersible platform drilling rigs.

LCTX vs VAL — Head-to-Head

Bigger by revenue
LCTX
LCTX
1.3× larger
LCTX
$6.6M
$5.2M
VAL
Growing faster (revenue YoY)
VAL
VAL
+275.5% gap
VAL
405.9%
130.4%
LCTX
Higher net margin
VAL
VAL
13785.2% more per $
VAL
13798.1%
12.9%
LCTX
More free cash flow
LCTX
LCTX
$28.8M more FCF
LCTX
$-5.3M
$-34.1M
VAL
Faster 2-yr revenue CAGR
LCTX
LCTX
Annualised
LCTX
113.9%
29.5%
VAL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LCTX
LCTX
VAL
VAL
Revenue
$6.6M
$5.2M
Net Profit
$851.0K
$717.5M
Gross Margin
-7850.0%
Operating Margin
-99.1%
Net Margin
12.9%
13798.1%
Revenue YoY
130.4%
405.9%
Net Profit YoY
126.0%
436.6%
EPS (diluted)
$0.00
$10.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LCTX
LCTX
VAL
VAL
Q4 25
$6.6M
$5.2M
Q3 25
$3.7M
$5.6M
Q2 25
$2.8M
$700.0K
Q1 25
$1.5M
Q4 24
$2.9M
$-1.7M
Q3 24
$3.8M
$3.9M
Q2 24
$1.4M
$4.8M
Q1 24
$1.4M
$2.6M
Net Profit
LCTX
LCTX
VAL
VAL
Q4 25
$851.0K
$717.5M
Q3 25
$-29.8M
$188.1M
Q2 25
$-30.5M
$115.1M
Q1 25
$-4.1M
Q4 24
$-3.3M
$133.7M
Q3 24
$-3.0M
$64.6M
Q2 24
$-5.8M
$149.6M
Q1 24
$-6.5M
$25.5M
Gross Margin
LCTX
LCTX
VAL
VAL
Q4 25
-7850.0%
Q3 25
-7142.9%
Q2 25
-56428.6%
Q1 25
97.6%
Q4 24
94.6%
24529.4%
Q3 24
99.0%
-11748.7%
Q2 24
96.9%
-9039.6%
Q1 24
93.2%
-17007.7%
Operating Margin
LCTX
LCTX
VAL
VAL
Q4 25
-99.1%
Q3 25
-102.9%
Q2 25
-715.4%
Q1 25
-433.1%
Q4 24
-178.2%
Q3 24
-101.6%
Q2 24
-416.7%
Q1 24
-461.3%
Net Margin
LCTX
LCTX
VAL
VAL
Q4 25
12.9%
13798.1%
Q3 25
-809.0%
3358.9%
Q2 25
-1101.8%
16442.9%
Q1 25
-275.6%
Q4 24
-114.1%
-7864.7%
Q3 24
-80.3%
1656.4%
Q2 24
-409.1%
3116.7%
Q1 24
-453.0%
980.8%
EPS (diluted)
LCTX
LCTX
VAL
VAL
Q4 25
$0.00
$10.13
Q3 25
$-0.13
$2.65
Q2 25
$-0.13
$1.61
Q1 25
$-0.02
Q4 24
$0.00
$1.86
Q3 24
$-0.02
$0.88
Q2 24
$-0.03
$2.03
Q1 24
$-0.04
$0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LCTX
LCTX
VAL
VAL
Cash + ST InvestmentsLiquidity on hand
$55.8M
$599.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$44.5M
$3.2B
Total Assets
$112.6M
$5.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LCTX
LCTX
VAL
VAL
Q4 25
$55.8M
$599.4M
Q3 25
$40.5M
$662.7M
Q2 25
$42.3M
$503.4M
Q1 25
$47.9M
Q4 24
$47.8M
$368.2M
Q3 24
$32.7M
$379.3M
Q2 24
$38.5M
$398.3M
Q1 24
$43.6M
$494.1M
Stockholders' Equity
LCTX
LCTX
VAL
VAL
Q4 25
$44.5M
$3.2B
Q3 25
$22.0M
$2.4B
Q2 25
$48.4M
$2.3B
Q1 25
$79.0M
Q4 24
$78.4M
$2.2B
Q3 24
$66.2M
$2.1B
Q2 24
$68.3M
$2.2B
Q1 24
$72.4M
$2.0B
Total Assets
LCTX
LCTX
VAL
VAL
Q4 25
$112.6M
$5.3B
Q3 25
$89.6M
$4.6B
Q2 25
$90.8M
$4.5B
Q1 25
$111.8M
Q4 24
$113.2M
$4.4B
Q3 24
$96.6M
$4.3B
Q2 24
$102.8M
$4.4B
Q1 24
$108.5M
$4.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LCTX
LCTX
VAL
VAL
Operating Cash FlowLast quarter
$-4.9M
$72.2M
Free Cash FlowOCF − Capex
$-5.3M
$-34.1M
FCF MarginFCF / Revenue
-79.9%
-655.8%
Capex IntensityCapex / Revenue
6.0%
2044.2%
Cash ConversionOCF / Net Profit
-5.73×
0.10×
TTM Free Cash FlowTrailing 4 quarters
$-19.4M
$159.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LCTX
LCTX
VAL
VAL
Q4 25
$-4.9M
$72.2M
Q3 25
$-3.6M
$198.1M
Q2 25
$-5.5M
$120.0M
Q1 25
$-4.9M
Q4 24
$-6.3M
$124.6M
Q3 24
$-5.8M
$193.0M
Q2 24
$-5.2M
$11.5M
Q1 24
$-5.8M
$26.3M
Free Cash Flow
LCTX
LCTX
VAL
VAL
Q4 25
$-5.3M
$-34.1M
Q3 25
$-3.6M
$128.3M
Q2 25
$-5.6M
$52.8M
Q1 25
$-5.0M
Q4 24
$-6.7M
$12.9M
Q3 24
$-5.9M
$111.1M
Q2 24
$-5.2M
$-98.7M
Q1 24
$-5.8M
$-125.0M
FCF Margin
LCTX
LCTX
VAL
VAL
Q4 25
-79.9%
-655.8%
Q3 25
-98.6%
2291.1%
Q2 25
-200.8%
7542.9%
Q1 25
-331.8%
Q4 24
-234.0%
-758.8%
Q3 24
-156.1%
2848.7%
Q2 24
-371.2%
-2056.3%
Q1 24
-403.1%
-4807.7%
Capex Intensity
LCTX
LCTX
VAL
VAL
Q4 25
6.0%
2044.2%
Q3 25
0.3%
1246.4%
Q2 25
0.5%
9600.0%
Q1 25
6.5%
Q4 24
12.7%
-6570.6%
Q3 24
3.0%
2100.0%
Q2 24
3.6%
2295.8%
Q1 24
2.6%
5819.2%
Cash Conversion
LCTX
LCTX
VAL
VAL
Q4 25
-5.73×
0.10×
Q3 25
1.05×
Q2 25
1.04×
Q1 25
Q4 24
0.93×
Q3 24
2.99×
Q2 24
0.08×
Q1 24
1.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LCTX
LCTX

Collaboration Revenues$6.3M95%
Other$345.0K5%

VAL
VAL

Segment breakdown not available.

Related Comparisons